Italy’s SSN Agrees to Reimburse Secukinumab for Moderate to Severe Hidradenitis Suppurativa

Positive Phase III Sunshine and Sunrise trials showed clinically relevant reductions in inflammatory lesions alongside lower pain levels in adults unresponsive to standard therapy.